Treatment package time predicts cancer‑specific survival and distant metastasis in laryngeal cancer

AbstractMarital status has long been recognized as an important prognostic factor for many cancers, however its’ prognostic effect for patients with laryngeal cancer has not been fully examined. We retrospectively analyzed 8834 laryngeal cancer patients in the Surveillance Epidemiology and End Results database from 2004 to 2010. Patients were divided into four groups: married, widowed, single, and divorced/separated. The difference in overall survival (OS) and cancer-specific survival (CSS) of the various marital subgroups were calculated using the Kaplan–Meier curve. Multivariate Cox regression analysis screened for independent prognostic factors. Propensity score matching (PSM) was also conducted to minimize selection bias. We included 8834 eligible patients (4817 married, 894 widowed, 1732 single and 1391 divorced/separated) with laryngeal cancer. The 5-year OS and CSS of married, widowed, single, and separated/divorced patients were examined. Univariate and multivariate analyses found marital status to be an independent predictor of survival. Subgroup survival analysis showed that the OS and CSS rates in widowed patients were always the lowest in the various American Joint Committee on Cancer stages, irrespective of sex. Widowed patients demonstrated worse OS and CSS in the 1:1 matched group analysis. Among patients with laryngeal cancer, widowed patients represented the highest-risk group, with the lowest OS and CSS.

Download Full-text

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer

British Journal of Cancer ◽

10.1038/s41416-019-0589-0 ◽

2019 ◽

Vol 121 (9) ◽

pp. 776-785 ◽

Cited By ~ 2

Author(s):

Chitra Joseph ◽

Sara Al-Izzi ◽

Mansour Alsaleem ◽

Sasagu Kurozumi ◽

Michael S Toss ◽

...

Keyword(s):

Breast Cancer ◽

Patient Outcome ◽

Distant Metastasis ◽

Prognostic Significance ◽

Retinoid X Receptor ◽

Cancer Tissue ◽

Lower Grade ◽

Breast Cancer Specific Survival ◽

Cancer Specific Survival ◽

Er Positive

Abstract Background Retinoid X Receptor Gamma (RXRG) is a member of the nuclear receptor superfamily and plays a role in tumour suppression. This study aims to explore the prognostic significance of RXRG in breast cancer. Methods Primary breast cancer tissue microarrays (n = 923) were immuno-stained for RXRG protein and correlated with clinicopathological features, and patient outcome. Results Nuclear RXRG expression was significantly associated with smaller tumour size (p = 0.036), lower grade (p < 0.001), lobular histology (p = 0.016), lower Nottingham Prognostic Index (p = 0.04) and longer breast cancer-specific survival (p < 0.001), and longer time to distant metastasis (p = 0.002). RXRG expression showed positive association with oestrogen receptor (ER)-related biomarkers: GATA3, FOXA1, STAT3 and MED7 (all p < 0.001) and a negative correlation with the Ki67 proliferation marker. Multivariate analysis demonstrated RXRG protein as an independent predictor of longer breast cancer-specific survival and distant metastasis-free survival. In the external validation cohorts, RXRG expression was associated with improved patients’ outcome (p = 0.025). In ER-positive tumours, high expression of RXRG was associated with better patient outcome regardless of adjuvant systemic therapy. ER signalling pathway was the top predicted master regulator of RXRG protein expression (p = 0.005). Conclusion This study provides evidence for the prognostic value of RXRG in breast cancer particularly the ER-positive tumours.

Download Full-text

The effect of treatment package time in head and neck cancer patients treated with adjuvant radiotherapy and concurrent systemic therapy

World Journal of Otorhinolaryngology - Head and Neck Surgery ◽

10.1016/j.wjorl.2018.09.005 ◽

2019 ◽

Vol 5 (3) ◽

pp. 160-167 ◽

Cited By ~ 3

Author(s):

Ahmed I. Ghanem ◽

Matthew Schymick ◽

Souheyla Bachiri ◽

Aniruddh Mannari ◽

Jawad Sheqwara ◽

...

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Systemic Therapy ◽

Adjuvant Radiotherapy ◽

Effect Of Treatment ◽

Treatment Package ◽

Treatment Package Time

Download Full-text

Impact of Treatment Package Time and Distance to Treatment Facility in Patients with Newly-Diagnosed Glioblastoma Treated with Hypofractionated Chemoradiotherapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2020.07.2051 ◽

2020 ◽

Vol 108 (3) ◽

pp. e690

Author(s):

O. Padilla ◽

D. Smith ◽

E.J. Buss ◽

M.B. Sisti ◽

J.N. Bruce ◽

...

Keyword(s):

Newly Diagnosed ◽

Treatment Facility ◽

Newly Diagnosed Glioblastoma ◽

Treatment Package ◽

Treatment Package Time

Download Full-text

Anastomotic leakage after surgery for rectal cancer: a risk factor for local recurrence, distant metastasis and reduced cancer-specific survival?

Colorectal Disease ◽

10.1111/j.1463-1318.2009.02136.x ◽

2011 ◽

Vol 13 (3) ◽

pp. 272-283 ◽

Cited By ~ 42

Author(s):

F. Jörgren ◽

R. Johansson ◽

L. Damber ◽

G. Lindmark

Keyword(s):

Rectal Cancer ◽

Risk Factor ◽

Local Recurrence ◽

Anastomotic Leakage ◽

Distant Metastasis ◽

Cancer Specific Survival

Download Full-text

The Effect of Treatment Package Time in Head and Neck Cancer Patients Treated with Adjuvant Radiation Therapy and Concurrent Systemic Therapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.06.1408 ◽

2017 ◽

Vol 99 (2) ◽

pp. E338

Author(s):

A.I. Ghanem ◽

A. Mannari ◽

M.A. Schymick ◽

C. Burmeister ◽

T. Ghanem ◽

...

Keyword(s):

Radiation Therapy ◽

Head And Neck Cancer ◽

Head And Neck ◽

Cancer Patients ◽

Systemic Therapy ◽

Adjuvant Radiation ◽

Adjuvant Radiation Therapy ◽

Effect Of Treatment ◽

Treatment Package ◽

Treatment Package Time

Download Full-text

Evaluating the Prognostic Factors Associated with Cancer-specific Survival of Differentiated Thyroid Carcinoma Presenting with Distant Metastasis

Annals of Surgical Oncology ◽

10.1245/s10434-012-2711-x ◽

2012 ◽

Vol 20 (4) ◽

pp. 1329-1335 ◽

Cited By ~ 51

Author(s):

Brian Hung-Hin Lang ◽

Kai Pun Wong ◽

Chung Yeung Cheung ◽

Koon Yat Wan ◽

Chung-Yau Lo

Keyword(s):

Prognostic Factors ◽

Thyroid Carcinoma ◽

Distant Metastasis ◽

Differentiated Thyroid Carcinoma ◽

Cancer Specific Survival ◽

Factors Associated

Download Full-text

Salvage Surgery following Radiation Failure for Laryngeal Cancer in Elderly Patients

Otolaryngology ◽

10.1177/0194599811414396 ◽

2011 ◽

Vol 145 (5) ◽

pp. 759-766 ◽

Cited By ~ 4

Author(s):

Jonathan J. Lusardi ◽

Paula M. Buchanan ◽

Kara M. Christopher ◽

Mark A. Varvares

Keyword(s):

Overall Survival ◽

Laryngeal Cancer ◽

Salvage Surgery ◽

Survival Rates ◽

Relative Survival ◽

Population Based ◽

Cancer Specific Survival ◽

Age Cohorts ◽

Data Registry ◽

Registry Analysis

Objective. To find the survival rate of patients ≥80 years old who undergo salvage surgery for squamous cell carcinoma of the larynx. Study Design. National data registry analysis. Setting. Seventeen population-based registries comprising the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Subjects and Methods. Overall, cancer-specific, and relative survival rates were calculated from 1418 patients, stratified into 3 age cohorts, who underwent surgery following radiation therapy for treatment of laryngeal cancer. Results. The 1-year overall survival of patients ≥80 years old (n = 57) was 76.1%. The cancer-specific survival at 1 year was 86.4%. These survival rates were significantly less than those of patients <65 years old (n = 869), who had a 1-year overall survival of 88.1% ( P = .006) and cancer-specific survival of 90.5% ( P = .029). Patients aged between 65 and 79 years old (n = 492) displayed 1-year overall survival of 80.7% ( P = .426) and cancer-specific survival of 85.1% ( P = .711), which were not significantly different from the ≥80 year cohort. When comparing relative survival at 5 years, the ≥80-year-old cohort’s survival trended the highest (≥80 years, 62.8%; 65-79 years, 51.3%; 20-64 years, 56.2%). Conclusion. While patients ≥80 years old have a less favorable prognosis than patients <65 years old, the survival rates of patients ≥80 years old are not significantly different from the 65- to 79-year-old cohort. After controlling for non-cancer-related death, patients ≥80 years old appear to have similar 5-year survival outcomes compared with other patients.

Download Full-text

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

Journal of Clinical Oncology ◽

10.1200/jco.2012.45.2615 ◽

2013 ◽

Vol 31 (19) ◽

pp. 2382-2387 ◽

Cited By ~ 527

Author(s):

Kevin S. Hughes ◽

Lauren A. Schnaper ◽

Jennifer R. Bellon ◽

Constance T. Cirrincione ◽

Donald A. Berry ◽

...

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Distant Metastasis ◽

Early Stage ◽

Breast Cancer Specific Survival ◽

Cancer Specific Survival ◽

Er Positive ◽

Long Term Follow Up

Purpose To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer. Patients and Methods Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) –positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women). Primary end points were time to local or regional recurrence, frequency of mastectomy, breast cancer–specific survival, time to distant metastasis, and overall survival (OS). Results Median follow-up for treated patients is now 12.6 years. At 10 years, 98% of patients receiving TamRT (95% CI, 96% to 99%) compared with 90% of those receiving Tam (95% CI, 85% to 93%) were free from local and regional recurrences. There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer–specific survival, or OS between the two groups. Ten-year OS was 67% (95% CI, 62% to 72%) and 66% (95% CI, 61% to 71%) in the TamRT and Tam groups, respectively. Conclusion With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains. However, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tam remains a reasonable option for women age ≥ 70 years with ER-positive early-stage breast cancer.

Download Full-text